EASTBOURNE Registry: Use of Sirolimus-Coated Balloons in Coronary Artery Disease

The introduction of drug coated balloons (DCB) has become an innovative therapeutic alternative to current treatments. Paclitaxel-coated balloons (PCB) have been used to treat in-stent restenosis (ISR) and also approach CAD in native arteries. More recently, sirolimus-coated balloons (SCB) are being looked at as part of pilot studies and smaller registries with preliminary results. 

Registro EASTBOURNE: Utilización de Balones Cubiertos de Sirolimus en enfermedad coronaria

The aim of this prospective multicenter registry was to assess the role of the new SCBs in the treatment of CAD.

Primary end point was defined as the need for target lesion revascularization (TLR) at 12 months, characterized by target lesion reintervention with 70% stenosis and the presence of ischemia in fictional tests. Secondary end points were procedural success, free of in hospital complications such as acute MI at followup; cardiac death, and major adverse cardiovascular events (MACE), a combination of TLR, acute MI and cardiac death.

Between 2016 and 2020, 2,123 patients were enrolled, totaling 2,440 lesions. Mean age was 66.6 years, with a larger percentage of men. There was diabetes in 41.5% of cases, multivessel disease in 51.9%, a history of prior MI and PCI in 42.9% and 66.3%, respectively. In terms of clinical presentation, 53.5% presented stable CAD, while 46.6% presented acute coronary syndrome. De novo lesions in small vessels were treated in 56% of cases, while 44% showed ISR.   

Read also: Left Atrial Appendage Closure: As Effective in Men and Women?

Primary end point was seen in 5.9% of vessels, more often in patients with ISR vs patients with compromised natural vessels (10.5% vs 2.0%; RR: 1.90; CI 95%: 1.13-3.19; P < 0.001). All-cause mortality rate, cardiac death, acute MI and BARC bleeding 3 or 5 were 2.5%, 1.5%, 2.4% and 0.7%, respectively. MACE rate was 9.9% (4.9% in de novo lesion patients and 14.9% in ISR patients; P < 0.001). After multivariable Cox regression model, the main factors behind TLR were ISR (OR: 5.5; CI del 95%: 3.382-8.881), and vessel reference diameter. 

Conclusion

The EASTBOURNE registry has shown the safety and efficacy at midterm of sirolimus DCB in a wide range of patients with CAD.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Sirolimus-Coated Balloon in an All-Comer Population of Coronary Artery Disease Patients The EASTBOURNE Prospective Registry.

Reference: Bernardo Cortese, MD et al J Am Coll Cardiol Intv 2023;16:1794–1803.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...